Medical treatment of small cell lung cancer: State of the art and new development

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 15, 2013, Pages 2019-2031

  Sgambato, Assunta ^a   Casaluce, Francesca ^a   Maione, Paolo ^b   Rossi, Antonio ^b   Sacco, Paola Claudia ^b   Panzone, Filomena ^b   Ciardiello, Fortunato ^a   Gridelli, Cesare ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

Author keywords

Amrubicin; First line; Maintenance treatment; Second line; Small cell lung cancer; Targeted therapy

Indexed keywords

ALPHA INTERFERON; AMRUBICIN; ANTHRACYCLINE; ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; BMS 833923; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IPILIMUMAB; IRINOTECAN; ISOSORBIDE; LOMUSTINE; METHOTREXATE; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PACLITAXEL; PEMETREXED; SONIDEGIB; TENIPOSIDE; THALIDOMIDE; TOPOTECAN; VINCRISTINE; VISMODEGIB;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CHEMOSENSITIVITY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG ERUPTION; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; GERIATRIC DISORDER; HUMAN; HYPERTENSION; INFECTION; KIDNEY INJURY; LUNG SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SEPSIS; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; SMALL CELL LUNG CARCINOMA;

EID: 84884554668     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.823401     Document Type: Review

References (94)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44
2. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-96
3. Patel AM, Dunn WF, Trastek VF. Staging systems of lung cancer. Mayo Clin Proc 1993;68:475-82
4. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-41
5. Fruh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;1-7. doi:10.1093/annonc/mdt178
6. Rossi A, Martelli O, Di Maio M. Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev 2013;39(5):498-506
7. Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988;15:278-99
8. Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: a multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987;107(4):451-8
9. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83(12):855-61
10. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10(2):282-91
11. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17(6):1794-801
12. Johnson D. Management of small cell lung cancer: current state of the art. Chest 1999;116(Suppl):525S-30S
13. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years'follow-up. J Clin Oncol 2002;20(24):4665-72
14. Baka S, Califano R, Ferraldeschi R, et al. Phase III randomized trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 2008;99(3):442-7
15. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83(1):8-15
16. Amarasena IU, Walters JA, Wood-Baker R, et al. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev 2008(4):CD006849
17. Johnson SW, O'Dwyer PJ. Pharmacology of cancer chemotherapy: cisplatin and its analogues. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 7th edition. Lippincott Williams & Wilkins; Philadelphia, PA: 2005. p. 344-58
18. Joss RA, Alberto P, Hurny C, et al. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine: Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1995;6:41-8
19. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer: a Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5:601-7
20. Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007;97:162-9
21. Lee SM, James LE, Qian W, et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax 2009;64:75-80
22. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30:1692-8
23. Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000;30:23-36
24. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 2002;346:85-91
25. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-43
26. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-5
27. Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008;26(26):4261-7
28. Schmittel A, Sebastian M, Fischer von Weikersthal L, et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 2011;22(8):1798-804
29. Shao N, Jin S, Zhu W. An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2012;7:470-2
30. Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009;27(28):4787-92
31. O'Brien ME, Konopa K, Lorigan P, et al. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer-EORTC 08062. Eur J Cancer 2011;47(15):2322-30
32. Shipley D, Hainsworth JD, Mekhail T, et al. Amrubicin and carboplatin with pegfilgrastim in patients with extensive-stage small-cell lung cancer (ESSCLC): a phase II study of the Sarah Cannon Research Institute (SCRI) [abstract 7100]. Presented at ASCO Annual Meeting; 2012
33. Kotani Y, Satouchi M, Ando M, et al. A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC): JCOG0509 [abstract 7003]. Presented at ASCO Annual Meeting; 2012
34. Sun Y, Cheng Y, Hao X, et al. Result of phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small cell lung cancer. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2013;31(15-Suppl):abstract 7507
35. Loehrer PJ Sr, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995;13(10):2594-9
36. Pujol JL, Daures JP, Riviere A, et al. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001;93(4):300-8
37. Miyamoto H, Nakabayashi T, Isobe H, et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 1992;49(6):431-5
38. Niell HB, Herndon JE II, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005;23(16):3752-9
39. Mavroudis D, Papadakis E, Veslemes M, et al. Greek Lung Cancer Cooperative Group. A multicenter randomized clinical trial comparing paclitaxel-cisplatinetoposide versus cisplatin-etoposide as first-line treatment in patients with smallcell lung cancer. Ann Oncol 2001;12:463-70
40. Stathopoulos G, Traphalis D, Dimitroulis J, et al. Combination of three cytotoxic agents in small cell lung cancer. Cancer Chemother Pharmacol 2013;71(2):413-18
41. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24(1):75-83
42. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15(23):7412-20
43. Bristol-Myers Squibb. Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone (ClinicalTrials.gov Identifier: NCT01450761). Available from: http://www.clinicaltrials.gov/ct2/show/ NCT01450761? term=NCT01450761&rank=1 [Last accessed 14 May 2013]
44. Jiang J, Shi HZ, Deng JM, et al. Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: a meta-analysis of the published literature. Lung Cancer 2009;65:214-18
45. Messori A, Trippoli S, Tendi E. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. J Clin Pharm Ther 1996;21:57-63
46. Berghmans T, Paesmans M, Lafitte JJ, et al. Role of granulocyte and granulocyte-macrophage colonystimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 2002;37:115-23
47. Bozcuk H, Artac M, Ozdogan M, Savas B. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC). A metaanalysis of the published controlled trials. Cancer 2005;104:2650-7
48. Rossi A, Garassino MC, Cinquini M, et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010;70:119-28
49. Cheng S, Evans WK, Stys-Norman D, et al. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007;2:348-54
50. Kim YH, Mishima M. Second-line chemotherapy for small-Cell Lung Cancer (SCLC). Cancer Treat Rev 2011;37:143-50
51. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67
52. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7
53. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:1743-9
54. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-92
55. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: north Japan lung cancer study group trial 0402. J Clin Oncol 2008;26:5401-6
56. Jotte R, Conkling P, Reynolds C, et al. Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy. Presented at 2009 ASCO Meeting. J Clin Oncol 2009;27:abstract 8028
57. Jotte R, von Pawel J, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). Presented at 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2011;29(15-Suppl):abstract 7000
58. Saito R, Inoue A, Sugawara S, et al. Phase II study of amrubicin (AMR) combined with carboplatin (CBDCA) for refractory relapsed small cell lung cancer (SCLC): North Japan Lung Cancer Group 0802 [abstract 7086]. Presented at ASCO 2012; 2012
59. Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009;27(12):2046-51
60. Ciuleanu T, Samarzjia M, Demidchik Y, et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. J Clin Oncol 2010;28(15 Suppl):abstract 7002
61. Metro G, Duranti S, Fischer MJ, et al. Emerging drugs for small cell lung cancer-an update. Expert Opin Emerging Drugs 2012;17(1):31-6
62. Califano R, Abidin AZ, Peck R, et al. Management of small cell lung cancer recent developments for optimal care. Drugs 2012;72(4):471-90
63. Patton JF, Spigel DR, Greco FA, et al. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): update of a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2006;24(18 Suppl):7085
64. Spigel DR, Hainsworth JD, Farley C, et al. Tracheoesophageal (TE) fistula development in a phase II trial of concurrent chemoradiation (CRT) and bevacizumab (B) in limited-stage smallcell lung cancer (LS-SCLC). J Clin Oncol 2008;26(15 Suppl):7554
65. Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27:6006-11
66. Spigel DR, Greco FA, Zubkus JD, et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 2009;4(12):1555-60
67. Ready NE, Dudek AZ, Pang HH, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 2011;29:4436-41
68. Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011;29(16):2215-22
69. Bevacizumab in Extensive Small Cell Lung Cancer. Available from: http:/clinicaltrials.gov/ct2/results? term=NCT00930891 [Last accessed 27 May 2013]
70. Pujol JL, Breton JL, Gervais R, et al. Phase III doubleblind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007;25(25):3945-51
71. Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009;101(15):1049-57
72. Yan JJ, Chen FF, Tsai YC, et al. Immunohistochemical detection of Bcl-2 protein in small cell carcinomas. Oncology 1996;53(1):6-11
73. Jiang SX, Kameya T, Sato Y, et al. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol 1996;148(3):837-46
74. Rudin CM, Salgia R, Wang X, et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensivestage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008;26(6):870-6
75. Langer CJ, Albert I, Kovacs P, et al. A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC) [abstract]. J Clin Oncol 2011;29:7001
76. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev 2008;22(18):2454-72
77. Edwards DK, Allen KE, Arora S, et al. Mechanism for Gli1-induced resistance to combination cisplatin and etoposide in small-cell lung cancer [abstract]. Undergraduate Research Poster Symposium; 2011
78. Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC). Available from: http://www.clinicaltrials.gov/ct2/ show/NCT01579929?term=hedgehog&cond=small+cell+lung+cancer&rank=2 [Last access 27 May 2013]
79. A Study of LY2940680 in Small Cell Lung Cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01722292?term=hedgehog&cond= small+cell+lung+cancer&rank=3 [Last access 27 May 2013]
80. Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00887159?term= hedgehog&cond=small+cell+lung+cancer&rank=1 [Last access 27 May 2013]
81. A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer. Available from: http://www.clinicaltrials. gov/ct2/show/NCT00927875? term=hedgehog&cond=small+cell+lung +cancer&rank=4 [Last access 27 May 2013]
82. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327(23):1618-24
83. Schild SE, Stella PJ, Brooks BJ, et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer 2005;103(11):2349-54
84. Janssen-Heijnen MLG, Maas HAAM, van de Schans SAM, et al Chemotherapy in elderly small-cell lung cancer patients: yes we can, but should be do it? Ann Oncol 2011 22 4 821-6
85. Murray N, Gratt C, Shah A, et al. Abbreviated treatment for elderly, infirm or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 1998;16(10):3323-8
86. Jeremic B, Shibamoto Y, Acimovic L, et al. Carboplatin, etoposide and accelerated hyperfractionated radiotherapy
87. NCCN Guidelines version 2.2013. Small Cell Lung Cancer
88. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999;341(7):476-84
89. Crossen JR, Garwood D, Glatstein E, et al. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation induced encephalopathy. J Clin Oncol 1994;12(3):627-42
90. Rossi A, Maione P, Colantuoni G, et al. Treatment of small cell lung cancer in the elderly. Oncologist 2005;10(6):399-411
91. Ardizzoni A, Favaretto A, Boni L, et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis-a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 2005;23(3):569-75
92. Igawa S, Ryuge S, Fukui T, et al. Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer. Int J Clin Oncol 2010;15(5):447-52
93. Inoue A, Ishimoto O, Fukumoto S, et al. A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: north Japan Lung Cancer Study Group Trial 0405. Ann Oncol 2010;21(4):800-3
94. Nakao M, Oguri T, Suzuki T, et al. Amrubicin monotherapy for elderly patients with previously treated lung cancer. Intern Med 2010;49(17):1857-62